US Stock MarketDetailed Quotes
SNDX Syndax Pharmaceuticals
- 21.060
- +0.490+2.38%
Close Apr 26 16:00 ET
- 21.060
- 0.0000.00%
Post 17:32 ET
1.79BMarket Cap-7067P/E (TTM)
21.235High20.475Low775.08KVolume20.590Open20.570Pre Close16.26MTurnover0.92%Turnover RatioLossP/E (Static)84.98MShares25.34052wk High3.23P/B1.78BFloat Cap11.21552wk Low--Dividend TTM84.64MShs Float29.860Historical High--Div YieldTTM3.70%Amplitude3.390Historical Low20.978Avg Price1Lot Size
Syndax Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -20.14%-160.6M | -80.61%-41.35M | -56.44%-44.65M | 12.24%-35.37M | 6.45%-39.23M | -558.88%-133.68M | -122.73%-22.89M | -14.43%-28.54M | -67.63%-40.31M | -85.63%-41.93M |
| Net income from continuing operations | -40.19%-209.36M | -84.91%-72.47M | -44.47%-51.15M | -18.75%-44.62M | -10.65%-41.13M | -699.13%-149.34M | -140.74%-39.19M | -71.53%-35.4M | -64.00%-37.57M | -34.07%-37.17M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | 51.93%-187K | --0 | --0 | --0 | ---187K |
| Depreciation and amortization | -63.64%12K | 0.00%3K | -62.50%3K | -72.73%3K | -72.73%3K | -23.26%33K | -70.00%3K | 0.00%8K | 22.22%11K | -31.25%11K |
| Other non cash items | -51.51%739K | 116.96%243K | -73.43%237K | -42.25%149K | -58.02%110K | 714.97%1.52M | 123.73%112K | 291.23%892K | 19.44%258K | 21.86%262K |
| Change In working capital | 1,823.91%31.86M | 86.20%26.01M | -39.60%1.59M | 171.10%4.75M | 94.13%-486K | 117.26%1.66M | 1,006.89%13.97M | 132.54%2.63M | -39.42%-6.67M | -508.95%-8.27M |
| -Change in receivables | ---- | ---- | -145.53%-3.9M | 127.55%1.89M | 133.26%2.08M | ---- | ---- | --8.56M | ---6.84M | ---6.26M |
| -Change in prepaid assets | 122.75%676K | -15.84%3.96M | -36.30%-3.74M | -169.69%-2.44M | 134.39%2.9M | -113.20%-2.97M | 6,006.49%4.7M | -409.71%-2.74M | 306.31%3.5M | -1,177.42%-8.43M |
| -Change in payables and accrued expense | 152.75%20.48M | 39.17%11.42M | 389.80%9.23M | 259.02%5.3M | -185.18%-5.47M | 64.34%8.1M | 592.15%8.2M | -193.84%-3.19M | -22.94%-3.33M | 109.60%6.42M |
| -Change in other working capital | 408.18%10.71M | ---- | ---- | ---- | ---- | 73.55%-3.47M | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -20.14%-160.6M | -80.61%-41.35M | -56.44%-44.65M | 12.24%-35.37M | 6.45%-39.23M | -558.88%-133.68M | -122.73%-22.89M | -14.43%-28.54M | -67.63%-40.31M | -85.63%-41.93M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 163.17%117.61M | 88.16%-16.29M | 689.97%40.08M | 247.97%73.91M | 143.40%19.92M | -355.53%-186.19M | -129.55%-137.63M | -125.51%-6.79M | -330.39%-49.95M | 127.99%8.18M |
| Net PPE purchase and sale | --0 | --0 | ---- | ---- | ---- | 274.42%225K | --0 | ---- | ---- | ---- |
| Net investment purchase and sale | 163.09%117.61M | 88.16%-16.29M | 671.06%40.08M | 247.97%73.91M | 143.40%19.92M | -357.52%-186.41M | -130.04%-137.63M | -126.35%-7.02M | -330.39%-49.95M | 127.99%8.18M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 163.17%117.61M | 88.16%-16.29M | 689.97%40.08M | 247.97%73.91M | 143.40%19.92M | -355.53%-186.19M | -129.55%-137.63M | -125.51%-6.79M | -330.39%-49.95M | 127.99%8.18M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 53.34%264.13M | 58.09%258.48M | 113.69%1.85M | -93.90%1.32M | 344.17%2.47M | 45.41%172.25M | 48.94%163.5M | -893.26%-13.53M | 260.80%21.72M | -41.98%557K |
| Net issuance payments of debt | --0 | --0 | ---- | ---- | ---- | ---21M | --2K | ---- | ---- | ---- |
| Net common stock issuance | 42.29%258.09M | 59.35%258.09M | --0 | ---- | ---- | 110.10%181.39M | 99.45%161.96M | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | -49.09%6.04M | -74.69%389K | -75.23%1.85M | -42.26%1.32M | 344.17%2.47M | -62.41%11.86M | -94.51%1.54M | 338.30%7.47M | 157.93%2.29M | -41.98%557K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 53.34%264.13M | 58.09%258.48M | 113.69%1.85M | -93.90%1.32M | 344.17%2.47M | 45.41%172.25M | 48.94%163.5M | -893.26%-13.53M | 260.80%21.72M | -41.98%557K |
| Net cash flow | ||||||||||
| Beginning cash position | -66.47%74.47M | 32.56%94.77M | -19.00%97.49M | -69.49%57.63M | -66.47%74.47M | 92.51%222.08M | -0.08%71.49M | 76.59%120.35M | 192.85%188.89M | 92.51%222.08M |
| Current changes in cash | 249.81%221.14M | 6,641.99%200.84M | 94.42%-2.73M | 158.16%39.86M | 49.27%-16.84M | -238.31%-147.61M | -98.02%2.98M | -1,540.51%-48.86M | -1,975.08%-68.53M | 34.73%-33.19M |
| End cash Position | 296.95%295.61M | 296.95%295.61M | 32.56%94.77M | -19.00%97.49M | -69.49%57.63M | -66.47%74.47M | -66.47%74.47M | -0.08%71.49M | 76.59%120.35M | 192.85%188.89M |
| Free cash flow | -20.14%-160.6M | -80.61%-41.35M | -56.44%-44.65M | 12.24%-35.37M | 6.45%-39.23M | -560.92%-133.68M | -122.76%-22.89M | -14.43%-28.54M | -67.63%-40.31M | -85.63%-41.93M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg